1,000 UK adults a year have to give up work because of the condition.
Rheumatoid arthritis is a condition that mainly affects the body’s joints, causing inflammation, pain and swelling. It can be make movement very difficult, and 1,000 UK adults a year have to give up work because of the condition.
BiP is a protein that occurs naturally in the body. It’s a substance that reduces inflammation, and although it’s found in the joints of arthritis sufferers, they don’t have it in large enough amounts for it to be effective. The trial is testing the effects on sufferers of an intravenous dose of BiP.
If it works as we expect, then a single dose could be enough to relieve the worst of the symptoms for several months. There are 800,000 appointments every year for existing sufferers of Rheumatoid Arthritis, and over 80,000 for new patients. Which means that, if effective, this drug could make a huge difference to the quality of tens of thousands of people’s lives, whilst also freeing up time and resources within the NHS.